Clinical trials: Underweight

Multiple Sclerosis

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

• Active, not recruiting
• Age: 10 to 17 years
• Phase 3
• Results posted

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)

Trial name

NCT01892722

Testing

Interferon beta-1a, Fingolimod

Where

73 sites in United States, Australia and 23 more

Volunteers

240 people

Sponsor

Novartis Pharmaceuticals